Wall Street brokerages expect that Sio Gene Therapies, Inc. (NASDAQ:SIOX) will report earnings of ($0.19) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Sio Gene Therapies’ earnings. The highest EPS estimate is ($0.02) and the lowest is ($0.35). Sio Gene Therapies posted earnings per share of ($0.54) during the same quarter last year, which would suggest a positive year over year growth rate of 64.8%. The company is expected to issue its next quarterly earnings report on Wednesday, June 9th.

According to Zacks, analysts expect that Sio Gene Therapies will report full-year earnings of ($0.78) per share for the current fiscal year, with EPS estimates ranging from ($0.98) to ($0.61). For the next year, analysts expect that the firm will post earnings of ($0.92) per share, with EPS estimates ranging from ($1.16) to ($0.77). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Sio Gene Therapies.

Sio Gene Therapies (NASDAQ:SIOX) last announced its earnings results on Monday, February 8th. The company reported ($0.20) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.09.

Several equities research analysts have recently commented on the company. SVB Leerink lifted their target price on Sio Gene Therapies from $7.00 to $8.00 and gave the company an “outperform” rating in a research note on Wednesday, December 16th. Zacks Investment Research lowered shares of Sio Gene Therapies from a “buy” rating to a “hold” rating in a research note on Tuesday, February 16th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $11.45.

Shares of SIOX traded down $0.13 during mid-day trading on Tuesday, hitting $2.91. 55,223 shares of the company traded hands, compared to its average volume of 1,725,592. The stock has a market capitalization of $137.50 million and a price-to-earnings ratio of -1.54. The business has a 50-day moving average of $2.97 and a 200 day moving average of $3.07. Sio Gene Therapies has a one year low of $1.41 and a one year high of $5.74.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new position in Sio Gene Therapies during the fourth quarter worth about $32,000. Lindbrook Capital LLC bought a new stake in Sio Gene Therapies during the 3rd quarter worth approximately $60,000. ExodusPoint Capital Management LP acquired a new stake in Sio Gene Therapies during the 4th quarter worth approximately $88,000. Prelude Capital Management LLC bought a new position in Sio Gene Therapies in the fourth quarter valued at approximately $95,000. Finally, Wells Fargo & Company MN bought a new stake in shares of Sio Gene Therapies during the fourth quarter worth $100,000. Institutional investors and hedge funds own 24.12% of the company’s stock.

About Sio Gene Therapies

Sio Gene Therapies, Inc, a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis.

See Also: Pattern Day Trader

Get a free copy of the Zacks research report on Sio Gene Therapies (SIOX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sio Gene Therapies (NASDAQ:SIOX)

Receive News & Ratings for Sio Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sio Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.